Provisions of global consensus on menopausal hormone therapy: Goal and rationale


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper provides a clinical appraisal of the data of the U.S. Woman’s Health Initiative (WHI) study that has played a negative role in the fate of hormone replacement therapy (HRT). More than 10 years of intensive analysis, reanalysis of the data of the WHI and new randomized clinical trials have elapsed. This could create concepts of the role of a temporal factor in the use and efficiency of HRT and confirm the notion of its exposure window. The findings are a guide to create a global consensus on menopausal hormone therapy with the participation of 6 leading medical associations. The paper gives the main points of the consensus and their interpretation.

全文:

受限制的访问

作者简介

Vera Smetnik

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: verasmetnik@mail.ru
MD, Professor, Main research fellow in Department of gynecological endocrinology

参考

  1. Grodstein F., Manson J.E., Colditz G.A., Willett W.c., Speizer F.E., Stampfer M.J.A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 2000; 133(12): 933-41.
  2. Rossouw J.E., Anderson G.E., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.
  3. Clarkson Т.В. The new conundrum: do estrogens have any cardiovascular benefits? Int. J. Fertil. Womens Med. 2002; 47(2): 61-8.
  4. Karas R.H., Clarkson Т.В. Considerations in interpreting the cardiovascular effects of hormonal replacement therapy observed in the WHI: timing is everything. J. Menopausal Med. 2003; 10(1): 8-12.
  5. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13): 1465-77.
  6. Manson J.E., Bassuk S.S. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am. J. Epidemiol. 2007; 166(5): 511-7.
  7. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. Br. Med. J. 2012; 345: e6409.
  8. Dinger J., Heinemann К. The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. In: 13th World of congress on menopause. Rome, 8-11 June 2011.
  9. Harman S.M. New finding from the Knoros Early Prevention Study (KEEPS) randomized trial. In: The North American Menopause Society (NAMS) 23-rd Annual meeting. Orlando, Florida, 3-6 October 2012.
  10. de Villiers T.J., Gass M.L., Haines C.J., Hall J.F., Lobo P.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4.
  11. Mariinez Pérez J.A., Palacios S., Chavida F., Pérez M. Severity of menopausal symptoms and cardiovascular and osteoporosis risk factors. Climacteric. 2013; 16(2): 226-34.
  12. de Villiers T.J., Pines A., Panay N., Gambacciani М., Archer D.F., Baber R.J. et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.
  13. ACOG Practice Bulletin No.141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16.
  14. Panay N., Hamoda H., Arya R., Savvas М. The 2013 British Menopause Society and Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2): 59-68.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##